Immunovant, Inc.

NasdaqGS:IMVT Stock Report

Market Cap: US$4.0b

Immunovant Valuation

Is IMVT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IMVT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IMVT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IMVT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IMVT?

Key metric: As IMVT is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for IMVT. This is calculated by dividing IMVT's market cap by their current book value.
What is IMVT's PB Ratio?
PB Ratio9.4x
BookUS$449.05m
Market CapUS$3.99b

Price to Book Ratio vs Peers

How does IMVT's PB Ratio compare to its peers?

The above table shows the PB ratio for IMVT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average88.7x
CRSP CRISPR Therapeutics
2.2x34.5%US$4.2b
TPTX Turning Point Therapeutics
4.8x24.7%US$3.8b
RYZB RayzeBio
6.5x2.0%US$3.7b
RYTM Rhythm Pharmaceuticals
341.1x66.7%US$3.8b
IMVT Immunovant
9.4x8.3%US$4.0b

Price-To-Book vs Peers: IMVT is good value based on its Price-To-Book Ratio (9.4x) compared to the peer average (116.6x).

Price to Book Ratio vs Industry

How does IMVT's PB Ratio compare vs other companies in the US Biotechs Industry?

59 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$588.69m
AMRN Amarin
0.4x-7.7%US$205.50m
IMAB I-Mab
0.4x1.8%US$77.18m
MGX Metagenomi
0.3x-23.2%US$75.22m
IMVT 9.4xIndustry Avg. 1.9xNo. of Companies73PB01.63.24.86.48+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: IMVT is expensive based on its Price-To-Book Ratio (9.4x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is IMVT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IMVT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio9.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IMVT's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IMVT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$28.73
US$48.93
+70.3%
12.4%US$58.00US$36.00n/a15
Nov ’25US$29.39
US$48.60
+65.4%
12.0%US$60.00US$36.00n/a15
Oct ’25US$28.45
US$49.07
+72.5%
10.0%US$60.00US$41.00n/a14
Sep ’25US$30.90
US$48.43
+56.7%
8.1%US$57.00US$41.00n/a14
Aug ’25US$28.87
US$49.14
+70.2%
7.4%US$57.00US$42.00n/a14
Jul ’25US$27.51
US$49.14
+78.6%
7.4%US$57.00US$42.00n/a14
Jun ’25US$25.39
US$50.43
+98.6%
6.4%US$57.00US$44.00n/a14
May ’25US$28.52
US$50.87
+78.4%
7.6%US$57.00US$40.00n/a15
Apr ’25US$31.61
US$50.65
+60.2%
7.3%US$57.00US$40.00n/a17
Mar ’25US$35.30
US$50.73
+43.7%
7.7%US$57.00US$40.00n/a15
Feb ’25US$36.07
US$50.23
+39.3%
8.0%US$57.00US$40.00n/a13
Jan ’25US$42.13
US$50.23
+19.2%
8.0%US$57.00US$40.00n/a13
Dec ’24US$40.55
US$49.33
+21.7%
8.7%US$57.00US$40.00n/a12
Nov ’24US$33.47
US$48.92
+46.2%
9.1%US$57.00US$40.00US$29.3912
Oct ’24US$38.39
US$40.67
+5.9%
27.0%US$54.00US$18.00US$28.4512
Sep ’24US$23.99
US$29.92
+24.7%
13.8%US$34.00US$18.00US$30.9012
Aug ’24US$23.07
US$29.54
+28.0%
12.9%US$34.00US$18.00US$28.8713
Jul ’24US$18.97
US$28.23
+48.8%
12.4%US$32.00US$18.00US$27.5113
Jun ’24US$20.68
US$26.50
+28.1%
26.7%US$32.00US$4.00US$25.3914
May ’24US$17.62
US$24.86
+41.1%
27.7%US$31.00US$4.00US$28.5214
Apr ’24US$15.51
US$24.50
+58.0%
30.1%US$31.00US$4.00US$31.6112
Mar ’24US$17.50
US$23.30
+33.1%
33.9%US$31.00US$4.00US$35.3010
Feb ’24US$18.20
US$18.25
+0.3%
53.1%US$30.00US$4.00US$36.078
Jan ’24US$17.75
US$15.00
-15.5%
62.8%US$30.00US$4.00US$42.139
Dec ’23US$13.87
US$13.00
-6.3%
59.9%US$30.00US$4.00US$40.559
Nov ’23US$11.51
US$9.56
-17.0%
40.7%US$16.00US$4.00US$33.479

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

7D

2.4%

1Y

20.0%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$59.39

7D

7.8%

1Y

20.6%

IQVIA Holdings

US$36.5b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

7D

3.6%

1Y

-5.8%